Accordingly, the anti-CTLA4 antibody can be usually considered as a common ICB agent for improved PDIT, which can inhibit tumor immune escape by effectively blocking CTLA4 on the surface of T cells, further activating a large number of CD8+ T cells to eliminate tumors. Here, CD8A is linked to neoplasm.